Pre-Seed · Round open
We tell reversible acute deterioration apart from neurodegenerative progression by comparing each patient against their own personal baseline — not a population threshold.
Deepleey S.r.l. — Italy, 2026
The clinical context
Patients with Alzheimer’s and senile dementia who are still semi-independent stay at home, where there is no continuous clinical observation between visits.
An acute cognitive decline can have a reversible cause (infection, medication, dehydration, delirium) or be the onset of neurodegenerative progression. From the outside, at first, they look the same.
Between one visit and the next there is no structured clinical observation: families and caregivers are left alone to read the signals.
A late differential diagnosis means either a reversible therapy missed, or an unnecessary alarm for a transient episode — either way, a growing burden on the caregiver.
Cognitive Twin
The proprietary core is a computational model of the individual, updated daily through structured voice interaction, ambient computer vision and behavioral data.
The disease progresses: the patient’s baseline evolves over time. Deviation detection is built to model this non-stationarity, not to assume a fixed reference.
We tell reversible acute deterioration apart from neurodegenerative progression by looking at how the signal changes: sudden onset vs. gradual drift, fluctuating vs. monotonic, single- vs multi-domain.
An off-the-shelf tablet and two ambient cameras, about €800 per installation. The architecture exposes a standard interface: any compatible device becomes a Duomea agent.
The infrastructure — multimodal ingestion, personal baseline, deviation detection, clinical reporting — is designed to be condition-agnostic, not tied to a single use case.
Clinical validation
The clinical study that generates the proprietary longitudinal dataset and validates the deviation-detection model.
The team
Founder & Chief AI
Models, ML pipelines, Cognitive Twin architecture.
Chief Technical Officer
Digital twin architecture, product and technical direction.
Clinical & Regulatory
MDR, CER/CEP/PMCF — previously IIT, Movendo.
Senior Data Scientist
Clinical and behavioral data modeling.
Co-founder & Chief Strategy and Ecosystem Officer
Stakeholder ecosystem, patient/caregiver engagement, institutional partnerships, adoption.
Commercial & Capital
Enterprise IT, prior VC fundraising and M&A exits.
In recruiting
Track record in clinical evidence → reimbursement. Equity 8–12%, board seat.
Gabriele Torre and Giuseppe Russo remain operationally active on the project; their stake is indirect, through Deepleey S.r.l.
The round
To close the IRCCS term sheet, launch the sponsor-funded clinical study and complete the CEO search. Full materials — deck, cap table, use of proceeds — available on request.
Contact
For the full investor deck, the data room, or an introductory call.
Deepleey S.r.l. — Italy